When expression of NF1 is inhibited, the resulting ER+ breast cancer cells were stimulated by tamoxifen (a drug commonly used to prevent relapses from ER+ breast cancer) instead of inhibited, and these cells became sensitive to a very low concentration of estradiol151. Here, ESR1 is linked to breast carcinoma.